Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal…
15 Sep 2025
AstraZeneca halts £200m research investment in Cambridge
AstraZeneca has halted its planned £200m ($270m) investment in a research facility in Cambridge, UK, according to reports from Reuters. The investment, which was anticipated to generate 1,000 new jobs,…
15 Sep 2025
FDA chief blames decades of regulatory failure for misleading pharma ads
The US Food and Drug Administration (FDA) commissioner Martin Makary has described the current state of direct-to-consumer pharmaceutical advertising as a “public health crisis” in the US, citing lax regulatory…
15 Sep 2025
Amneal secures FDA approval for sodium oxybate solution
US-based Amneal Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its 500mg/mL sodium oxybate oral solution. The solution is prescribed for managing cataplexy and excessive…
12 Sep 2025
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut
US-based biotech LB Pharmaceuticals has broken the 2025 biotech initial public offering (IPO) drought – and with style – raising $285m via a public listing on the US stock market.…
12 Sep 2025
AbbVie extends Rinvoq exclusivity by four years after generics settlements
AbbVie has bolstered the sales outlook of its blockbuster autoimmune drug Rinvoq (upadacitinib) by extending its exclusivity until 2037. The company accomplished the feat via settlements with generics manufacturers who…
12 Sep 2025
Kashiv signs deal with CRISTÁLIA for Xolair biosimilar in LATAM
Kashiv BioSciences has entered a partnership with Brazilian biopharmaceutical firm CRISTÁLIA to facilitate the marketing of ADL-018/Omalizumab, a proposed biosimilar to Genentech and Novartis’ Xolair, across Latin America (LATAM). Kashiv…